Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rapid Micro Biosystems (RPID) EBITDA Margin (2020 - 2025)

Rapid Micro Biosystems' EBITDA Margin history spans 6 years, with the latest figure at 145.09% for Q3 2025.

  • For Q3 2025, EBITDA Margin rose 1324.0% year-over-year to 145.09%; the TTM value through Sep 2025 reached 148.77%, up 4946.0%, while the annual FY2024 figure was 177.96%, 7322.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 145.09% at Rapid Micro Biosystems, up from 167.28% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 124.47% in Q4 2024 and bottomed at 394.6% in Q4 2022.
  • The 5-year median for EBITDA Margin is 202.15% (2024), against an average of 238.94%.
  • The largest annual shift saw EBITDA Margin crashed -18742bps in 2022 before it soared 20227bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 279.49% in 2021, then crashed by -41bps to 394.6% in 2022, then soared by 51bps to 192.33% in 2023, then soared by 35bps to 124.47% in 2024, then dropped by -17bps to 145.09% in 2025.
  • Per Business Quant, the three most recent readings for RPID's EBITDA Margin are 145.09% (Q3 2025), 167.28% (Q2 2025), and 161.85% (Q1 2025).